08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

InSite, Bess Royalty, SWK Holdings deal

InSite said it received a $1 million milestone payment from Bess Royalty and the SWK Funding LLC subsidiary of SWK due to 2013 net sales of Besivance besifloxacin ophthalmic solution reaching undisclosed levels....
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

InSite, Bausch + Lomb, Bess Royalty, SWK Holdings deal

InSite sold its royalty on sales of Besivance besifloxacin ophthalmic solution to Bess Royalty and the SWK Funding LLC subsidiary of SWK for up to $16 million. InSite will receive $15 million at...
07:00 , Aug 15, 2011 |  BioCentury  |  Strategy

InSite's new vision

InSite Vision Inc. thought it was poised for success in 2007 when, after 20 years of effort and more than $52 million raised from investors, the company's first drug, AzaSite 1% azithromycin ophthalmic solution, was...
23:37 , Jul 13, 2011 |  BC Extra  |  Financial News

InSite plans to raise $22.2 million

Ophthalmic company InSite Vision Inc. (OTCBB:INSV) plans to raise $22.2 million through the sale of 37 million units at $0.60 per share. Each unit comprises a share and a five-year warrant to purchase 0.4 shares,...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

Besivance besifloxacin ophthalmic solution regulatory update

Bausch & Lomb said FDA approved an NDA for Besivance besifloxacin 0.06% ophthalmic suspension to treat bacterial conjunctivitis. An FDA advisory committee voted unanimously to recommend approval of the fluoroquinolone antimicrobial agent in December (see...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Clinical News

Besifloxacin ophthalmic solution regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously to recommend approval for 0.6% besifloxacin ophthalmic suspension to treat bacterial conjunctivitis. The PDUFA date is undisclosed. Bausch & Lomb plans to launch the fluoroquinolone antimicrobial...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

Besifloxacin ophthalmic solution regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on Dec. 5 to discuss an NDA from Bausch & Lomb for besifloxacin ophthalmic solution to treat bacterial conjunctivitis. Besifloxacin is a fluoroquinolone antimicrobial agent. Bausch...
08:00 , Jan 5, 2004 |  BC Week In Review  |  Company News

InSite, Bausch & Lomb deal

ISV sold to BOL its ISV-403 to treat ocular bacterial infections. ISV received a cash payment and reimbursement for product development expenses, and is eligible for royalties. The sale cancels the companies' 2002 deal,...
07:00 , May 5, 2003 |  BC Week In Review  |  Clinical News

ISV-403: Phase I

ISV began a double-blind, placebo-controlled dose-ranging Phase I trial in 48 healthy volunteers. The compound is partnered with BOL, which has exclusive rights to ISV-403 worldwide, excluding Asia, under a 2002 deal. SSP Co. Ltd....
08:00 , Feb 17, 2003 |  BC Week In Review  |  Clinical News

ISV-403: Phase I

ISV filed an IND to start Phase I trials of ISV-403 in the second quarter of 2003. As a result of the filing, ISV will receive an equity investment from BOL, which has exclusive rights...